Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Clinical Trial ID NCT01909453

Rank	Title	Journal	Year	PubWeight™‹?›
1	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.	Biomed Res Int	2015	1.25
2	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.	Onco Targets Ther	2015	0.99
3	Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.	Mol Cancer Ther	2014	0.92
4	Targeting drivers of melanoma with synthetic small molecules and phytochemicals.	Cancer Lett	2015	0.88
5	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.	Ther Adv Med Oncol	2016	0.87
6	Small molecule drugs with immunomodulatory effects in cancer.	Hum Vaccin Immunother	2015	0.86
7	MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.	Semin Oncol	2015	0.85
8	Resistance to Raf inhibition in cancer.	Drug Discov Today Technol	2014	0.79
9	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.	Oncotarget	2015	0.79
10	Novel melanoma therapy.	Exp Hematol Oncol	2016	0.79
11	Targeted Therapies in Melanoma: Translational Research at Its Finest.	J Invest Dermatol	2015	0.78
12	SEOM guidelines for the management of Malignant Melanoma 2015.	Clin Transl Oncol	2015	0.77
13	New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.	Drug Healthc Patient Saf	2014	0.77
14	Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.	Oncotarget	2016	0.76